Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    Open Studies | pancreatic disease | NIDDK
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | pancreatic disease | NIDDK
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders
Condition: Cystic Fibrosis
Intervention:
2 Recruiting Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Condition: Post-ERCP Pancreatitis
Interventions: Other: Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement;   Other: Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
3 Recruiting Mesenchymal Stem Cell and Islet Co-transplantation
Conditions: Chronic Pancreatitis;   Diabetes
Intervention: Biological: autologous mesenchymal stromal cell
4 Not yet recruiting MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
Conditions: Cystic Fibrosis Liver Disease;   Pancreatic Insufficiency
Intervention: Procedure: MRI
5 Recruiting Blood Flow and Vascular Function in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Acute (1 hour) Sildenafil;   Drug: Sub-Chronic (4 weeks) Sildenafil;   Drug: Placebo
6 Recruiting CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism
Interventions: Drug: Glucagon;   Other: Placebo
7 Recruiting Natural History of Noncirrhotic Portal Hypertension
Conditions: Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
Intervention:
8 Recruiting Fat Malabsorption in Chronic Pancreatitis
Condition: Chronic Pancreatitis
Intervention: Drug: Creon36™
9 Recruiting Diagnosing and Treating Low Blood Sugar Levels
Conditions: Hypoglycemia;   Insulinoma
Intervention:
10 Recruiting BioEnergetics and Metabolomics in Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention:
11 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:
12 Recruiting Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
Condition: Cystic Fibrosis
Intervention:
13 Recruiting Genetic Modifiers of Cystic Fibrosis Related Diabetes
Condition: Cystic Fibrosis Related Diabetes
Intervention:
14 Not yet recruiting Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Conditions: Type 1 Diabetes;   Hypoglycemia;   Hyperglycemia;   Artificial Pancreas
Intervention: Device: Hyperglycemia Minimization Algorithm
15 Recruiting International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol
Condition: Diabetes Mellitus, Type 1
Intervention: Device: Artificial Pancreas
16 Not yet recruiting The International Diabetes Closed Loop (iDCL) Trial: Main Protocol
Condition: Type1 Diabetes Mellitus
Interventions: Device: Artificial Pancreas;   Other: Sensor Augmented Therapy;   Device: continuous glucose monitor (CGM)
17 Recruiting Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Device: Decision Support System
18 Recruiting USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D
Condition: Type 1 Diabetes Mellitus
Interventions: Device: DiAs with USS Virginia;   Device: Sensor-Augmented Pump Therapy (placebo)
19 Recruiting Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control
Condition: Diabetes Mellitus, Type 1
Intervention: Device: CLC

Study has passed its completion date and status has not been verified in more than two years.